Dianthus Therapeutics (NASDAQ:DNTH) Shares Break Above 200-Day Moving Average – Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $85.18 and traded as high as $85.92. Dianthus Therapeutics shares last traded at $85.81, with a volume of 1,679,417 shares traded.

Analyst Ratings Changes

DNTH has been the topic of a number of research analyst reports. Raymond James Financial reiterated a “strong-buy” rating and set a $134.00 price target on shares of Dianthus Therapeutics in a report on Thursday. Truist Financial raised their price objective on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. initiated coverage on Dianthus Therapeutics in a research note on Friday, September 11th. They set an “overweight” rating and a $135.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $158.00 target price on shares of Dianthus Therapeutics in a report on Thursday, October 15th. Finally, Citigroup started coverage on shares of Dianthus Therapeutics in a research report on Friday, September 4th. They issued a “buy” rating and a $156.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Dianthus Therapeutics has a consensus rating of “Buy” and an average price target of $128.77.

Dianthus Therapeutics Price Performance

The company has a fifty day moving average of $90.05 and a 200-day moving average of $85.57. The firm has a market capitalization of $4.71 billion, a PE ratio of -21.56 and a beta of 1.47.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.13. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. The firm had revenue of $1.21 million for the quarter, compared to the consensus estimate of $0.46 million. Equities analysts anticipate that Dianthus Therapeutics, Inc. will post -3.81 EPS for the current year.

Insiders Place Their Bets

In other Dianthus Therapeutics news, Director Simon Read sold 2,778 shares of Dianthus Therapeutics stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $117.55, for a total value of $326,553.90. Following the completion of the sale, the director directly owned 2,778 shares in the company, valued at $326,553.90. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Adam M. Veness sold 16,167 shares of Dianthus Therapeutics stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $110.38, for a total transaction of $1,784,513.46. Following the completion of the sale, the senior vice president owned 3,833 shares of the company’s stock, valued at $423,086.54. This trade represents a 80.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 72,596 shares of company stock worth $7,748,340 in the last quarter. Corporate insiders own 3.02% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. BlackRock Inc. bought a new position in Dianthus Therapeutics in the 2nd quarter worth $401,990,000. Wellington Management Group LLP lifted its position in Dianthus Therapeutics by 24.4% during the 2nd quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock worth $314,849,000 after acquiring an additional 634,099 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in Dianthus Therapeutics by 160.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company’s stock worth $64,474,000 after acquiring an additional 451,597 shares during the last quarter. Jennison Associates LLC bought a new stake in Dianthus Therapeutics during the first quarter valued at about $40,713,000. Finally, Pictet Asset Management Holding SA boosted its holdings in Dianthus Therapeutics by 86.9% during the third quarter. Pictet Asset Management Holding SA now owns 462,290 shares of the company’s stock valued at $40,705,000 after acquiring an additional 214,995 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.